Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AEMD 
Aethlon Medical Inc (AEMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: AEMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.02
1 Year Target Price $3.02
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.14% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.14M USD | Price to earnings Ratio - | 1Y Target Price 3.02 |
Price to earnings Ratio - | 1Y Target Price 3.02 | ||
Volume (30-day avg) 1 | Beta 1.92 | 52 Weeks Range 0.60 - 8.44 | Updated Date 09/15/2025 |
52 Weeks Range 0.60 - 8.44 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -63.64% | Return on Equity (TTM) -207.29% |
Valuation
Trailing PE - | Forward PE 0.21 | Enterprise Value -1181979 | Price to Sales(TTM) 2.37 |
Enterprise Value -1181979 | Price to Sales(TTM) 2.37 | ||
Enterprise Value to Revenue 1.07 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 2598710 | Shares Floating 2587822 |
Shares Outstanding 2598710 | Shares Floating 2587822 | ||
Percent Insiders 0.53 | Percent Institutions 6.03 |
Upturn AI SWOT
Aethlon Medical Inc
Company Overview
History and Background
Aethlon Medical, Inc. is a medical technology company focused on developing and commercializing devices to address unmet needs in global health and biodefense. It was founded in 1991 and has focused on creating innovative therapies for life-threatening diseases.
Core Business Areas
- Therapeutic Blood Filtration: Development and commercialization of the Hemopurifier, a device designed to remove viruses and exosomes from the blood.
- Exosome Research: Researching and developing technologies related to exosomes, including their role in disease and potential therapeutic applications.
Leadership and Structure
The company has a Board of Directors and an executive management team led by the CEO.
Top Products and Market Share
Key Offerings
- Hemopurifier: The Hemopurifier is Aethlon's lead product, designed to remove viruses and exosomes from a patient's bloodstream. As it is still in clinical trials and not yet broadly approved for commercial use, definitive market share is not yet established. Competitors: Baxter International, Fresenius Medical Care, and Asahi Kasei Medical.
Market Dynamics
Industry Overview
The therapeutic blood filtration market is driven by the need for effective treatments for infectious diseases and cancer. Exosome research is a rapidly growing field with applications in diagnostics and therapeutics.
Positioning
Aethlon Medical is positioned as an innovator in the therapeutic blood filtration and exosome research space. Their competitive advantage lies in the Hemopurifier's unique mechanism of action.
Total Addressable Market (TAM)
The TAM for therapeutic blood filtration and exosome-based therapies is estimated to be in the billions of dollars. Aethlon Medical is positioning itself to capture a portion of this market through its product development and clinical trials. TAM varies greatly depending on regulatory approvals and specific applications.
Upturn SWOT Analysis
Strengths
- Innovative technology (Hemopurifier)
- Focus on unmet medical needs
- Intellectual property protection
Weaknesses
- Limited financial resources
- Dependence on regulatory approvals
- Relatively small team
Opportunities
- Expansion of Hemopurifier applications
- Partnerships with larger pharmaceutical companies
- Government funding for biodefense applications
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BAX
- FMS
- AKAMF
Competitive Landscape
Aethlon Medical faces competition from larger, more established medical device companies. Aethlon's advantage lies in its innovative technology, but it needs to overcome financial and regulatory hurdles to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Aethlon Medical Inc's growth has been primarily driven by research and development activities.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates are highly variable due to the uncertainty surrounding the company's product pipeline.
Recent Initiatives: Recent initiatives include clinical trials for the Hemopurifier in various indications, and exosome research initiatives.
Summary
Aethlon Medical is a speculative investment driven by its innovative Hemopurifier technology. Its dependence on regulatory approval makes it a higher-risk investment. The company has a strong focus on research, but its financial resources are limited. Future success hinges on successful clinical trials and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Research
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aethlon Medical Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2001-01-02 | CEO, CFO, Chief Accounting Officer, Secretary & Director Mr. James B. Frakes M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 9 | Website https://www.aethlonmedical.com |
Full time employees 9 | Website https://www.aethlonmedical.com | ||
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.